Why the study?
To provide an evidence-based approach to the evaluation, management, and monitoring of dyslipidemias, consolidating and replacing the 2018 guideline.
The 2026 ACC/AHA guideline provides updated comprehensive recommendations for managing dyslipidemias, replacing the 2018 cholesterol guideline.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“While we want to try to optimize healthy lifestyle habits as the first step to lower cholesterol, we realize that if lipid numbers aren't within the desirable range after a period of lifestyle optimization, we should consider adding lipid-lowering medication earlier than we would have considered 10 years ago. Lower [LDL-C] for longer, just like lower blood pressure for longer, results in much greater protection against future heart attack and stroke risk.”
“In general, lower LDL is better, especially for people at increased risk for a heart attack or stroke. Clinical trials have clearly demonstrated significant benefits for reduction in cardiovascular events when LDL-C levels are even lower than recommended in previous guidelines.”
“Dyslipidemia, or high cholesterol, refers to abnormal levels of lipids. They can be a low HDL cholesterol, a high LDL cholesterol and elevated triglycerides or a combination. Now we have a much greater emphasis in our guidelines about lipoprotein(a), a cholesterol-like substance. Elevated Lp(a) is also one type of dyslipidemia. We know that each of these lipid abnormalities can contribute to the buildup of fatty deposits in the arteries, and that leads to both a higher risk of heart attack and stroke.”
Clinicians should integrate CAC gatekeeping, inflammation, Lp(a), and lifetime LDL-C into care; extends 2018 guideline with nuanced risk stratification.
AIM: The "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." METHODS: A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Blumenthal et al. (2026) conducted a review in Dyslipidemia. Guideline on the Management of Dyslipidemia was evaluated. The 2026 ACC/AHA guideline provides updated recommendations for the evaluation, management, and monitoring of individuals with dyslipidemias, replacing the 2018 blood cholesterol guideline.
Synapse has enriched 10 related papers. Consider them for comparative context: